Dr Reddy’s, Aurigene and Kainomyx to co-develop anti-malarials

[cafead]

via Dr Reddy's Laboratories, alongside its division Aurigene Pharmaceutical Services, has entered into a non-binding memorandum of understanding (MoU) with US-based Kainomyx to co-develop and co-commercialise an affordable anti-malarial drug.

article source